Rezolute (RZLT) Assets Average (2011 - 2026)
Rezolute recorded quarterly Assets Average of $132.0 million in Q1 2026, down 11.17% quarter-over-quarter from $148.6 million in Q4 2025, and up 27.74% year-over-year from $103.4 million in Q1 2025.
Rezolute's Assets Average history runs 16 years deep, the most recent figure standing at $132.0 million for Q1 2026.
- In Q1 2026, Assets Average rose 27.74% year-over-year to $132.0 million; the TTM figure through Mar 2026 stood at $132.0 million (up 27.74% YoY), while the FY2025 annual figure was $154.1 million, up 20.19% from the prior year.
- Assets Average came in at $132.0 million for Q1 2026 at Rezolute, down from $148.6 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $167.1 million in Q3 2025 to a low of $76.5 million in Q1 2022.
- A 5-year average of $125.2 million and a median of $128.1 million in 2024 frame the typical range for Assets Average.
- Across the five-year window, Assets Average soared 279.02% in 2022 and plunged 33.24% in 2024, its largest moves.
- Rezolute's Assets Average stood at $153.1 million in 2022, then declined by 29.73% to $107.6 million in 2023, then increased by 9.42% to $117.7 million in 2024, then gained by 26.28% to $148.6 million in 2025, then fell by 11.17% to $132.0 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $132.0 million, $148.6 million, and $167.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.05 Bn |
| 10 | Rezolute | 374.41 Mn | 374.41 Mn | - | 132.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 132.04 Mn |
| Dec 31, 2025 | 148.65 Mn |
| Sep 30, 2025 | 167.08 Mn |
| Jun 30, 2025 | 135.11 Mn |
| Mar 31, 2025 | 103.37 Mn |
| Dec 31, 2024 | 117.71 Mn |
| Sep 30, 2024 | 128.08 Mn |
| Jun 30, 2024 | 110.24 Mn |
| Mar 31, 2024 | 94.94 Mn |
| Dec 31, 2023 | 107.57 Mn |
| Sep 30, 2023 | 118.36 Mn |
| Jun 30, 2023 | 128.96 Mn |
| Mar 31, 2023 | 142.21 Mn |
| Dec 31, 2022 | 153.10 Mn |
| Sep 30, 2022 | 154.20 Mn |
| Jun 30, 2022 | 111.00 Mn |
| Mar 31, 2022 | 76.49 Mn |
| Dec 31, 2021 | 61.08 Mn |
| Sep 30, 2021 | 40.68 Mn |
| Jun 30, 2021 | 37.77 Mn |
| Mar 31, 2021 | 35.92 Mn |
| Dec 31, 2020 | 23.16 Mn |
| Sep 30, 2020 | 9.19 Mn |
| Jun 30, 2020 | 12.83 Mn |
| Mar 31, 2020 | 17.63 Mn |
| Dec 31, 2019 | 23.57 Mn |
| Sep 30, 2019 | 19.41 Mn |
| Jun 30, 2019 | 13.86 Mn |
| Mar 31, 2019 | 7.96 Mn |
| Dec 31, 2018 | 762,426.50 |
| Sep 30, 2018 | 1.79 Mn |
| Jun 30, 2018 | 3.82 Mn |
| Mar 31, 2018 | 5.73 Mn |
| Dec 31, 2017 | 8.06 Mn |
| Sep 30, 2017 | 10.21 Mn |
| Jun 30, 2017 | 10.71 Mn |
| Mar 31, 2017 | 10.37 Mn |
| Dec 31, 2016 | 10.00 Mn |
| Sep 30, 2016 | 10.48 Mn |
| Jun 30, 2016 | 9.85 Mn |
| Mar 31, 2016 | 8.66 Mn |
| Dec 31, 2015 | 8.85 Mn |
| Sep 30, 2015 | 10.22 Mn |
| Jun 30, 2015 | 11.66 Mn |
| Mar 31, 2015 | 11.39 Mn |
| Dec 31, 2014 | 8.49 Mn |
| Sep 30, 2014 | 6.84 Mn |
| Jun 30, 2014 | 6.84 Mn |
| Mar 31, 2014 | 4.21 Mn |
| Dec 31, 2013 | 1.50 Mn |
| Sep 30, 2013 | 983,770.50 |
| Jun 30, 2013 | 1.34 Mn |
| Sep 30, 2012 | 534,520.50 |
| Jun 30, 2012 | 538,724.50 |
| Mar 31, 2012 | 287,338.50 |
| Dec 31, 2011 | 294,633.50 |
| Sep 30, 2011 | 30,254.00 |